Last reviewed · How we verify
Elocon ointment
At a glance
| Generic name | Elocon ointment |
|---|---|
| Sponsor | LEO Pharma |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Plaque Test Comparing the Anti-psoriatic Effect of Marketed Products for Topical Use for Psoriasis Vulgaris (PHASE2)
- Evaluation of Efficacy and Safety of Enhanced External Counter-pulsation on Patients With Atopic Dermatitis and Inflammatory Skin Disease Requiring Wet Wrap Therapy (NA)
- Topical Steroids & Bacterial Decolonization for Radiation Dermatitis (PHASE2)
- Effectiveness of Association Mometasone Furoate 0.1% and Salicylic Acid 5% Compared With Mometasone Furoate (PHASE2)
- Role of Tofacitinib in Vitiligo Patients (EARLY_PHASE1)
- Carbon Dioxide（CO2）Fractional Laser Plus Photodynamic Therapy in Female Patients With Vulvar Lichen Sclerosus (NA)
- Vasoconstriction Trial With LEO 90100 Aerosol Foam (PHASE1)
- Comparison of Efficacy and Safety of 0.1% Tacrolimus and 0.1% Mometasone Furoate for Adult Vitiligo (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Elocon ointment CI brief — competitive landscape report
- Elocon ointment updates RSS · CI watch RSS
- LEO Pharma portfolio CI